GoKawiilModified tapeworm drug shows promise against endometriosis in mouse study
Researchers led by Kanako Hayashi at Washington State University modified niclosamide, an existing anti-parasitic drug, to target cells involved in endometriosis lesions and tested it in mice. The study, published in Advanced Healthcare Materials, found the altered compound reduced disease activity without relying on surgery or hormone therapy, the two main current treatment approaches.
GoKawiil's interpretation of the reporting above, not reported fact.
Existing endometriosis treatments often fail long-term and carry significant side effects, so a non-surgical, non-hormonal option could change care for an estimated 190 million people worldwide. Hayashi describes the results as a potential 'breakthrough,' while outside researcher Elise Courtois calls it a 'beautiful first step,' suggesting cautious optimism rather than a confirmed therapy, since the work has so far only been tested in mice.
- A modified version of the anti-parasitic drug niclosamide reduced endometriosis-related cell activity in mice.
- Current treatments—surgery and hormone therapy—are often ineffective long-term and come with complications.
- The approach could lead to a non-surgical, non-hormonal treatment option if validated in human trials.
Source: nature.com — Kreier, 2026-10-01
Published there as: “The 'missed disease' that affects 190 million: endometriosis drug shows early promise”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.